Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of two supplemental new animal drug applications (NADAs) filed by Novartis Animal Health US, Inc. The supplemental NADAs provide for removal of a 250-pound weight restriction and the addition of a reproductive caution statement to labeling of tiamulin medicated feeds used for the treatment or control of certain bacterial enteric diseases in swine.
This rule is effective January 2, 2009.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Cindy L. Burnsteel, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-276-8341, e-mail: email@example.com.End Further Info End Preamble Start Supplemental Information
Novartis Animal Health US, Inc., 3200 Northline Ave., suite 300, Greensboro, NC 27408, filed a supplement to NADA 139-472 for DENAGARD (tiamulin) Medicated Premixes used for the treatment or control of certain bacterial enteric diseases in swine. Novartis Animal Health US, Inc., also filed a supplement to NADA 141-011 for the use of DENAGARD (tiamulin) Medicated Premixes and Chlortetracycline Type A medicated articles to manufacture 2-way combination drug medicated swine feeds used for the treatment or control of certain bacterial enteric diseases. The supplemental NADAs provide for removal of a 250-pound weight restriction and the addition of a reproductive caution statement to labeling. The supplemental NADAs are approved as of December 9, 2008, and 21 CFR 558.600 is amended to reflect the approval.
Approval of these supplemental NADAs did not require review of additional safety or effectiveness data or information. Therefore, a freedom of information summary is not required.
The agency has determined under 21 CFR 25.33 that these actions are of a type that do not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.
This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801 808.Start List of Subjects
List of Subjects in 21 CFR Part 558End List of Subjects Start Amendment Part
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,End Amendment Part Start Part
PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDSEnd Part Start Amendment Part
1. The authority citation forEnd Amendment Part Start Amendment Part
2. In § 558.600, revise paragraphs (d)(2) and (e)(1)(i) to read as follows:End Amendment Part
(d) * * *
(2) The effects of tiamulin on swine reproductive performance, pregnancy, and lactation have not been determined.
(e) * * *
(1) * * *
|Tiamulin grams per ton||Combination in grams per ton||Indications for use||Limitations||Sponsor|
|(i) 10||For increased rate of weight gain and improved feed efficiency||Feed continuously as the sole ration. Not for use in swine weighing over 250 pounds||058198|
|* * * * * * *|
Dated: December 22, 2008.
Steven D. Vaughn,
Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.
[FR Doc. E8-31128 Filed 12-31-08; 8:45 am]
BILLING CODE 4160-01-S